Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License $3999.00
- Five User License $5299.00
- Corporate License $6299.00

Report description:

Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032?

Latin America Anti-Obesity Drugs Market Outlook?

The global anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032. The market is poised to secure a value of USD 6.3 billion by 2032, driven by the rising prevalence of obesity among children and teenagers across the region.

Key Takeaways
-According to the report released by the United Nations, Overview of Food Security and Nutrition 2022, almost one-fourth (22.5%) of the Latin American population is unable to afford a healthy meal in comparison to the world approximately priced at USD 3.89 per person per day.
-The increasing prevalence of obesity due to the adaption of a sedentary lifestyle along with unhealthy dietary habits are significant factors driving the Latin America anti-obesity drugs market growth in the forecast period.
-The regional market is witnessing high incidence of anti-obesity drugs, which is likely to boost the market share in the forecast period. In February 2023, Tesofensine received positive opinions from Mexican Food and Drug Administration.

Latin America Anti-Obesity Drugs Market Analysis

Obesity is a growing problem globally and is significantly contributing to high rates of health issues. Therefore, battling this condition is a major necessity of the hour. The Latin American region is facing major health issues related to obesity among children, teenagers, and adults. In August 2023, UNICEF released a report which highlighted that more than 4 million children aged 5 years or less were overweight in Latin American and Caribbean region.

Latin America anti-obesity drugs market share is estimated to be influenced by the approval of drugs by regional regulatory

authorities. For instance, in December 2019, Medix, a Mexican pharmaceutical company submitted a New Drug Application (NDA) to the Mexican Food and Drug Administration COFEPRIS (Comision Federal para la Proteccion contra Riesgos Sanitarios) for the approval of tesofensine (a monoamine uptake inhibitor), which can be used for treating obesity in patients. Tesofensine has demonstrated effective loss results in phase II studies in obese patients. After a long wait, on February 26, 2023, the tesofensine was provided a favourable opinion by the Mexican regulatory authority for the treatment of obese patients. Considering the efficacy provided by tesofensine in the clinical trial, a potential interest from both healthcare providers and patients is anticipated, propelling the market growth. The competitive landscape is also expected to be driven by the approval of tesofensine.

Latin America anti-obesity drugs market demand is likely to be propelled by the alarmingly increasing obesity rates. It has been highlighted that the current prevalence rate in Latin America is above the global average, and it has been rising over the last two decades at a sustained rate. Additionally, it contributes to various other health concerns such as hypertension, high cholesterol, diabetes, cardiovascular disease, and even cancer. Addressing obesity among people at early stages is a major precaution that can play a crucial role in timely treatments and overall increased the life expectancy of obese population in the region.

Latin America Anti-Obesity Drugs Market Segmentation??

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Drugs
-Semaglutide
-Phentermine/Topiramate
-Naltrexone/Bupropion
-Liraglutide
-Gelesis 100
-Orlistat
-Phentermine
-Methamphetamine
-Tirzepatide
Market Breakup by Drug Class
-Amphetamine
-GLP-1 Receptor Agonist
-Lipase Inhibitor
Market Breakup by Mechanism of Action
-Centrally Acting Drugs
-Peripherally Acting Drugs
Market Breakup by Route of Administration
-Oral
-Subcutaneous
Market Breakup by Prescription Type
-Prescription Drugs
-Over The Counter Drugs
Market Breakup by Distribution Channel
-Hospital Pharmacies
-Drug Store and Retail Pharmacies
-Online Pharmacies
Market Breakup by Country
-Brazil

-Argentina
-Mexico
-Others

Latin America Anti-Obesity Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:?

-VIVUS Inc.
-Pfizer, Inc.
-Novo Nordisk
-Bayer AG
-F Hoffmann-La-Roche
-Glaxosmithkline
-Arena Pharmaceuticals
-Eisai Co. Ltd
-Takeda Pharmaceutical Company
-Nalpropion Pharmaceuticals Inc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.?

FAQs
-What was the Latin America anti-obesity drugs market forecast outlook for 2024-2032???
The Latin America anti-obesity drugs market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 10.7% during the forecast period of 2024-2032, to reach a market value of USD 6.3 billion by 2032.

-What are the major factors aiding the Latin America anti-obesity drugs market demand? ?
Major factors aiding the market demand include the increasing prevalence of obesity along with diabetes mellitus among all age groups.

-What are the major Latin America anti-obesity drugs market trends??
One of the significant trends in the market is the increasing research and development activities and regulatory approvals to reduce the number of obese patients in the region. For instance, the approval of tesofensine by Mexican regulatory authorities for the treatment of obese patients.

-What is the market segmentation by drugs?
Based on drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine,
and Tirzepatide.???

-What drug classes are available in the market?
It includes amphetamines, GLP-1 receptor agonists, and lipase inhibitors.

-How many categories are based on the mechanism of action?
Mechanisms of action include centrally acting drugs and peripherally acting drugs.

-What are the various routes of administration for anti-obesity drugs? ?
Route of administration includes oral and subcutaneous.??

-What is the segmentation based on prescription types?
Type of prescriptions include prescription drugs and over-the-counter drugs.

-What is the market segmentation based on distribution channels?
Based on distribution channels, the market is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies.

-What is the market segmentation by country??
The market segmentation by countries includes Brazil, Argentina, Mexico, and others

Who are the key players involved in the Latin America anti-obesity drugs market?
The key players in the market are and VIVUS Inc., Nalpropion Pharmaceuticals Inc., Pfizer, Inc., Novo Nordisk, Bayer AG, F Hoffmann-La-Roche, GlaxoSmithKline, Arena Pharmaceuticals, Eisai Co. Ltd, Takeda Pharmaceutical Company.
Meta description
The Latin America anti-obesity drugs market size is poised for growth, driven by the expansion of the global market, which was valued at USD 2.5 billion in 2023 and is projected to grow at a CAGR of 10.70% during the forecast period of 2024-2032.

Table of Contents:

1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology

2 Executive Summary

3 Latin America Anti-Obesity Drugs Market Overview
- 3.1 Latin America Anti-Obesity Drugs Market Historical Value (2017-2023)
- 3.2 Latin America Anti-Obesity Drugs Market Forecast Value (2024-2032)

4 Latin America Anti-Obesity Drugs Market Landscape*
- 4.1 Latin America Anti-Obesity Drugs Market: Developers Landscape
  - 4.1.1 Analysis by Year of Establishment
  - 4.1.2 Analysis by Company Size
  - 4.1.3 Analysis by Region
- 4.2 Latin America Anti-Obesity Drugs Market: Product Landscape
  - 4.2.1 Analysis by Product
  - 4.2.2 Analysis by Material
  - 4.2.3 Analysis by Type

5 Latin America Anti-Obesity Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
  - 5.2.1 Strengths
  - 5.2.2 Weaknesses
  - 5.2.3 Opportunities
  - 5.2.4 Threats

5.3 Porter's Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Anti-Obesity Drugs Market Segmentation (2017-2032)
6.1 Latin America Anti-Obesity Drugs Market (2017-2032) by Drugs
6.1.1 Market Overview
6.1.2 Semaglutide
6.1.3 Phentermine/Topiramate
6.1.4 Naltrexone/Bupropion
6.1.5 Liraglutide
6.1.6 Gelesis 100
6.1.7 Orlistat
6.1.8 Phentermine
6.1.9 Methamphetamine
6.1.10 Tirzepatide
6.2 Latin America Anti-Obesity Drugs Market (2017-2032) by Drug Class
6.2.1 Market Overview
6.2.2 Amphetamine
6.2.3 GLP-1 receptor agonist
6.2.4 Lipase Inhibitor
6.3 Latin America Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
6.3.1 Market Overview
6.3.2 Centrally Acting Drugs
6.3.3 Peripherally Acting Drugs
6.4 Latin America Anti-Obesity Drugs Market (2017-2032) by Route of Administration
6.4.1 Market Overview
6.4.2 Oral
6.4.3 Subcutaneous
6.5 Latin America Anti-Obesity Drugs Market (2017-2032) by Prescription Type
6.5.1 Market Overview
6.5.2 Prescription Drugs
6.5.3 Over The Counter Drugs
6.6 Latin America Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Drug Store & Retail Pharmacies
6.6.4 Online Pharmacies
6.7 Latin America Anti-Obesity Drugs Market (2017-2032) by Countries
6.7.1 Market Overview
6.7.2 Brazil

6.7.3 Argentina
6.7.4 Mexico
6.7.5 Others
7 Brazil Anti-Obesity Drugs Market (2017-2032)
7.1 Brazil Anti-Obesity Drugs Market (2017-2032) by Drugs
7.1.1 Market Overview
7.1.2 Semaglutide
7.1.3 Phentermine/Topiramate
7.1.4 Naltrexone/Bupropion
7.1.5 Liraglutide
7.1.6 Gelesis 100
7.1.7 Orlistat
7.1.8 Phentermine
7.1.9 Methamphetamine
7.1.10 Tirzepatide
7.2 Brazil Anti-Obesity Drugs Market (2017-2032) by Drug Class
7.2.1 Market Overview
7.2.2 Amphetamine
7.2.3 GLP-1 receptor agonist
7.2.4 Lipase Inhibitor
7.3 Brazil Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
7.3.1 Market Overview
7.3.2 Centrally Acting Drugs
7.3.3 Peripherally Acting Drugs
7.4 Brazil Anti-Obesity Drugs Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Oral
7.4.3 Subcutaneous
7.5 Brazil Anti-Obesity Drugs Market (2017-2032) by Prescription Type
7.5.1 Market Overview
7.5.2 Prescription Drugs
7.5.3 Over The Counter Drugs
7.6 Brazil Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
7.6.1 Market Overview
7.6.2 Hospital Pharmacies
7.6.3 Drug Store & Retail Pharmacies
7.6.4 Online Pharmacies
8 Argentina Anti-Obesity Drugs Market (2017-2032)
8.1 Argentina Anti-Obesity Drugs Market (2017-2032) by Drugs
8.1.1 Market Overview
8.1.2 Semaglutide
8.1.3 Phentermine/Topiramate
8.1.4 Naltrexone/Bupropion
8.1.5 Liraglutide
8.1.6 Gelesis 100
8.1.7 Orlistat
8.1.8 Phentermine

8.1.9 Methamphetamine
8.1.10 Tirzepatide
8.2 Argentina Anti-Obesity Drugs Market (2017-2032) by Drug Class
8.2.1 Market Overview
8.2.2 Amphetamine
8.2.3 GLP-1 receptor agonist
8.2.4 Lipase Inhibitor
8.3 Argentina Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
8.3.1 Market Overview
8.3.2 Centrally Acting Drugs
8.3.3 Peripherally Acting Drugs
8.4 Argentina Anti-Obesity Drugs Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Oral
8.4.3 Subcutaneous
8.5 Argentina Anti-Obesity Drugs Market (2017-2032) by Prescription Type
8.5.1 Market Overview
8.5.2 Prescription Drugs
8.5.3 Over The Counter Drugs
8.6 Argentina Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
8.6.1 Market Overview
8.6.2 Hospital Pharmacies
8.6.3 Drug Store & Retail Pharmacies
8.6.4 Online Pharmacies
9 Mexico Anti-Obesity Drugs Market (2017-2032)
9.1 Mexico Anti-Obesity Drugs Market (2017-2032) by Drugs
9.1.1 Market Overview
9.1.2 Semaglutide
9.1.3 Phentermine/Topiramate
9.1.4 Naltrexone/Bupropion
9.1.5 Liraglutide
9.1.6 Gelesis 100
9.1.7 Orlistat
9.1.8 Phentermine
9.1.9 Methamphetamine
9.1.10 Tirzepatide
9.2 Mexico Anti-Obesity Drugs Market (2017-2032) by Drug Class
9.2.1 Market Overview
9.2.2 Amphetamine
9.2.3 GLP-1 receptor agonist
9.2.4 Lipase Inhibitor
9.3 Mexico Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
9.3.1 Market Overview
9.3.2 Centrally Acting Drugs
9.3.3 Peripherally Acting Drugs
9.4 Mexico Anti-Obesity Drugs Market (2017-2032) by Route of Administration
9.4.1 Market Overview

9.4.2 Oral
9.4.3 Subcutaneous
9.5 Mexico Anti-Obesity Drugs Market (2017-2032) by Prescription Type
9.5.1 Market Overview
9.5.2 Prescription Drugs
9.5.3 Over The Counter Drugs
9.6 Mexico Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
9.6.1 Market Overview
9.6.2 Hospital Pharmacies
9.6.3 Drug Store & Retail Pharmacies
9.6.4 Online Pharmacies
10 Regulatory Framework
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Funding and Investment Analysis
12.1 Analysis by Funding Instances
12.2 Analysis by Type of Funding
12.3 Analysis by Funding Amount
12.4 Analysis by Leading Players
12.5 Analysis by Leading Investors
12.6 Analysis by Geography
13 Partnership and Collaborations Analysis
13.1 Analysis by Partnership Instances
13.2 Analysis by Type of Partnership
13.3 Analysis by Leading Players
13.4 Analysis by Geography
14 Supplier Landscape
14.1 Market Share by Top 5 Companies
14.2 VIVUS Inc
14.2.1 Financial Analysis
14.2.2 Product Portfolio
14.2.3 Demographic Reach and Achievements
14.2.4 Mergers and Acquisitions
14.2.5 Certifications
14.3 Pfizer, Inc.
14.3.1 Financial Analysis
14.3.2 Product Portfolio
14.3.3 Demographic Reach and Achievements
14.3.4 Mergers and Acquisitions
14.3.5 Certifications
14.4 Novo Nordisk

14.4.1 Financial Analysis
14.4.2 Product Portfolio
14.4.3 Demographic Reach and Achievements
14.4.4 Mergers and Acquisitions
14.4.5 Certifications
14.5 Bayer AG
14.5.1 Financial Analysis
14.5.2 Product Portfolio
14.5.3 Demographic Reach and Achievements
14.5.4 Mergers and Acquisitions
14.5.5 Certifications
14.6 F Hoffmann-La Roche
14.6.1 Financial Analysis
14.6.2 Product Portfolio
14.6.3 Demographic Reach and Achievements
14.6.4 Mergers and Acquisitions
14.6.5 Certifications
14.7 Glaxosmithkline
14.7.1 Financial Analysis
14.7.2 Product Portfolio
14.7.3 Demographic Reach and Achievements
14.7.4 Mergers and Acquisitions
14.7.5 Certifications
14.8 Arena Pharmaceuticals
14.8.1 Financial Analysis
14.8.2 Product Portfolio
14.8.3 Demographic Reach and Achievements
14.8.4 Mergers and Acquisitions
14.8.5 Certifications
14.9 Eisai Co. Ltd
14.9.1 Financial Analysis
14.9.2 Product Portfolio
14.9.3 Demographic Reach and Achievements
14.9.4 Mergers and Acquisitions
14.9.5 Certifications
14.10 Takeda Pharmaceutical Company
14.10.1 Financial Analysis
14.10.2 Product Portfolio
14.10.3 Demographic Reach and Achievements
14.10.4 Mergers and Acquisitions
14.10.5 Certifications
14.11 Nalpropion Pharmaceuticals Inc
14.11.1 Financial Analysis
14.11.2 Product Portfolio
14.11.3 Demographic Reach and Achievements
14.11.4 Mergers and Acquisitions
14.11.5 Certifications

15 Latin America Anti-Obesity Drugs Market - Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
16 Key Opinion Leaders (KOL) Insights (Additional Insight)
17 Company Competitiveness Analysis (Additional Insight)
17.1 Very Small Companies
17.2 Small Companies
17.3 Mid-Sized Companies
17.4 Large Companies
17.5 Very Large Companies
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
18.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Latin America Anti-Obesity Drugs Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	$3999.00
	Five User License	$5299.00
	Corporate License	$6299.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	
		Date	2025-05-07
		Signature	